5 天前 - … homolog (KRAS), epidermal growth factor receptor (EGFR), … oncogenic RAS mutations
in adenocarcinomas. Mostly all … EGFR mutations in exon 21 are the missense mutations, …

5 天前 - … In our series, only 5.9% of patients with lung adenocarcinoma had KRAS mutations,
in … High prevalence of EGFR mutations in lung adenocarcinomas from Brazilian patients …

9 天前 - Clinical impact of EGFR and KRAS mutations in surgically treated unifocal and
multifocal lung adenocarcinoma - Jiang - Translational Lung Cancer Research … Clinical …

18 天前 - … KRAS) and epidermal growth factor receptor (EGFR). Roughly 40% of adenocarcinoma
harbor Kras activating mutations … there is a concomitant EGFR mutation; however, these …

30 天前 - … specificity in identifying lung adenocarcinomas with classic EGFR mutations, while
they … mutations in lung adenocarcinoma occurs in the KRAS gene and affects the EGFR/RAS/…

33 天前 - … stage, and driver gene mutations vary among different histopathological subtypes.
EGFR mutations are predominant in INMA, while KRAS mutations are predominant in IMA. …

36 天前 - … clinical Stage IA2-III lung adenocarcinomas and adenosquamous carcinomas with
one … 20 insertion, EGFR sensitizing mutations, KRAS G12C, RETfusion, and HER2 mutation. …

36 天前 - … KRAS and EGFR mutation status was available for 22pts. mPFS and mOS were
numerically longer in pts with KRAS … % (95% CI 4.1-36.5%) EGFR MUT vs wild type disease. …

36 天前 - … Background: Mutations in the human epidermal growth factor receptor 2 (ERBB2;
HER2) are oncogenic in lung adenocarcinoma (LUAD). An FDA-approved drug, trastuzumab …

36 天前 - … Background: Thyroid transcription factor 1 (TTF-1) expression is routinely
assessed in lung adenocarcinomas (LUAD) and is negative (TTF-1 Neg ) in 15-20% of cases. …